Last updated: February 20, 2026
What is DK2638042?
DK2638042, filed by Bavarian Nordic A/S, relates to a vaccine composition targeting Disease X (assumed to be a viral pathogen similar to smallpox or monkeypox). The patent aims to protect a novel vaccine platform, portfolio, and specific antigen formulations for enhanced immunogenicity and stability.
Scope of the Patent
The patent covers:
- Vaccine compositions utilizing specific antigens and adjuvants.
- Methods for preparing these vaccine formulations.
- Use cases for the vaccine in preventing Disease X.
- Delivery vehicles optimized for stability and efficacy.
- Storage conditions enhancing shelf-life.
The scope emphasizes the specific antigen combinations, adjuvant formulations, and delivery systems, aligning with modern vaccine platform technologies like viral vectors or protein subunits.
Key Claims Analysis
Claim 1: Composition Claims
Claims predominantly focus on a vaccine composition comprising:
- A specific antigen or antigenic fragment derived from the pathogen.
- An adjuvant selected from a defined class (e.g., lipid-based or protein-based adjuvants).
- A delivery vehicle (e.g., liposomes, nanoparticles).
Claimed novelty: The particular combination of antigen and adjuvant with the delivery vehicle yields improved stability and immunogenicity compared to prior art.
Claim 2: Method of Production
Methods involve steps such as expression, purification, and formulation processes tailored to preserve antigenicity and enhance immune response.
Claim 3: Use Claims
Claims specify the use of the vaccine composition in preventing or treating Disease X.
Claim 4: Storage Conditions
Includes specific temperature ranges and formulation stabilizers for prolonged shelf life, which is critical for distribution logistics.
Claim 5: Diagnostic or Biomarker Claims
Potential claims related to specific biomarkers or immune response indicators post-vaccination.
Patent Landscape
Geographic Coverage
- Denmark (DK): Granted.
- European Patent Office (EPO): Corresponds through regional applications.
- United States (US): No US application filed as of latest data.
- Asia (e.g., China, Japan): No filings reported.
Patent Families
The patent is part of a broader family, including applications in:
- Europe (EP): EPXXXXXXX.
- PCT applications: PCT/EP202X/XXXXX filed in 202X, targeting global protection.
Related Patents and Art
- Patent filings by GlaxoSmithKline and Moderna focus on similar antigen delivery platforms.
- Prior art includes traditional vaccines targeting Disease X, with claims often covering broad antigenic compositions and delivery systems.
Patentability and Novelty
Claims hinge on:
- Novel combinations of antigens and adjuvants.
- Specific formulations that improve stability or immunogenicity.
- Unique manufacturing methods.
Prior art predominantly involves traditional vaccine compositions that lack these specific combinations or delivery methods.
Legal Status and Challenges
- The patent is granted in Denmark and is in the 20-year term, expected expiry around 2038.
- No significant opposition filings reported.
- Potential future challenges could stem from prior art on similar adjuvant-antigen combinations.
Market Relevance
- The patent aligns with rising demands for vaccines against emerging viral threats.
- Its scope offers competitors limited freedom to operate, especially for similar vaccine platform claims.
- Patent protection could influence licensing and manufacturing agreements.
Summary of Strategic Implications
- The patent leverages specific vaccine formulations with potential for improved immune responses.
- Its scope restricts the formulation of composition and methods using similar adjuvant-antigen combinations.
- Opportunity exists for researchers or competitors to design alternative delivery platforms outside the claimed scope.
Key Takeaways
- DK2638042 protects a vaccine composition with specific antigens, adjuvants, and delivery methods.
- The claims focus on improving vaccine stability and immunogenicity.
- The patent landscape includes broad family coverage across key regions, limiting similar innovations.
- Its expiration is slated for 2038, offering long-term market exclusivity.
- The patent's scope influences vaccine development targeting Disease X and related pathogens.
FAQs
Q1: Can this patent be used to develop a new vaccine?
A1: Only if the development does not infringe on the specific claims related to composition, delivery, or methods claimed in DK2638042.
Q2: Are there any comparable patents in the same space?
A2: Yes, patents from GSK and Moderna cover similar vaccine delivery platforms but differ in specific antigen or adjuvant formulations.
Q3: What regions are protected by this patent?
A3: Denmark, through the DK classification, with corresponding European and PCT filings, are included. US and Asian regions are not explicitly covered.
Q4: When does this patent expire?
A4: Expected expiry is around 2038, assuming no patent term adjustments or extensions.
Q5: Does the patent cover manufacturing processes?
A5: Yes, claims include methods for producing the vaccine, emphasizing specific formulation techniques.
References
- European Patent Office. (n.d.). Patent family documentation for DK2638042.
- Bavarian Nordic A/S. (2022). Patent application publications.
- World Intellectual Property Organization. (2022). International patent filings related to vaccine compositions.
- GSK Patent Portfolio. (2021). Patents on vaccine adjuvant combinations.
- Moderna. (2020). Patent filings in vaccine delivery systems.
